Department of Medical Oncology, Virgen de las Nieves University Hospital, Granada 18014, Spain.
Institute of Biopathology and Regenerative Medicine (IBIMER), University of Granada, Granada 18016, Spain.
World J Gastroenterol. 2021 Oct 21;27(39):6515-6521. doi: 10.3748/wjg.v27.i39.6515.
In this editorial, we comment on pancreatic cancer (PC), one of the most aggressive and lethal cancers. Only minimal improvements in survival rates have been achieved over recent years. Available chemotherapeutic regimens have little impact, and surgical resection remains the only reliable curative approach. We address current treatment options for these patients, focusing on the usefulness of gene mutation as a prognostic biomarker and predictor of response to chemotherapy. Superior survival outcomes have been reported in patients with PC and mutant gene treated with first-line platinum-based chemotherapy. Therefore, it appears appropriate to include gene status among clinical criteria used to select the chemotherapy regimen. In addition, maintenance treatment with poly(ADP-ribose) polymerase inhibitors has been found to improve progression-free survival in patients with PC and mutated whose disease does not progress after first-line platinum-based chemotherapy. This combination has therefore been proposed as the optimal treatment regimen for these patients.
在这篇社论中，我们将对胰腺癌（PC）进行评论，这是一种最具侵袭性和致命性的癌症之一。近年来，生存率仅略有提高。现有的化疗方案影响甚微，手术切除仍然是唯一可靠的治愈方法。我们将针对这些患者的当前治疗选择进行讨论，重点关注基因突变作为预后生物标志物和化疗反应预测因子的作用。接受一线基于铂类的化疗治疗的具有突变基因的 PC 患者的生存结果得到了显著改善。因此，似乎可以将基因状态纳入用于选择化疗方案的临床标准中。此外，在一线基于铂类的化疗后疾病未进展的具有突变基因的 PC 患者中，使用聚（ADP-核糖）聚合酶抑制剂进行维持治疗已被发现可以改善无进展生存期。因此，该联合方案已被提议作为这些患者的最佳治疗方案。
